Search

22 Feb 2023: Spin-out PredictImmune wins £4.3m from Wellcome to evaluate its prognostic test. ... Published studies indicate that there are likely to be significant clinical and economic benefits in the use of biomarker tests to guide first line treatment based on

22 Feb 2023: PredictImmune has carried out considerable market research into the medical need for the tests and the health economic benefits that they will deliver. ... Tags:Image: Test tubes. Stay in touch with the latest updates from Cambridge Enterprise.

9 Feb 2023: Her first company, Psynova (acquired by Myriad Genetics in 2011), developed a blood test to diagnose psychiatric conditions, particularly schizophrenia. ... We did release a diagnostic blood test for schizophrenia, but unfortunately it has not survived

21 Mar 2023: London Economics, one of Europe’s leading specialist economics and policy consultancies, was commissioned to assess the University’s economic impact through a range of activities. ... This report by London Economics is a comprehensive attempt to

22 Feb 2023: useful, scaleable test by looking at whole blood samples in conjunction with CD8 T-cells and using widely-available technology. ... They found the new test was 90-100% accurate in correctly identifying patients who did not require multiple treatments.

22 Feb 2023: Cambridge researcher gets green light for while-you-wait Hep B test. Share:. ... Other tests in the pipeline include rapid tests for the detection of HIV and influenza.

17 Jan 2023: Gone fishing: highly accurate test for common respiratory viruses uses DNA as ‘bait’. ... In comparison, PCR (polymerase chain reaction) tests, while highly specific and accurate, can only test for one virus at a time and take several hours to return

22 Feb 2023: greatest societal and economic benefit from that world beating research. ... greatest societal and economic benefit from that world beating research.”.

22 Feb 2023: The focus of the US patent is on the biological mechanism of the test, which demonstrates whether a patient does or does not exhibit T cell exhaustion. ... tests in these devastating and chronic diseases and further enables our US commercial strategy.

23 Feb 2023: billions of miniaturised tests in tiny picodroplets. ... Among other things, the technology allows tests on individual cells as well as whole “libraries” of cells.

23 Feb 2023: This year, the Fund made seed investments in two new Cambridge spin-outs: Sphere Fluidics, which is developing droplets that serve as ‘miniature test tubes’, and PneumaCare, which has developed a

22 Feb 2023: The business, which spun out of the University of Cambridge, is focused on capturing hidden economic insights that exist in online data, giving clients a comprehensive overview of what is changing

23 Feb 2023: miniature test tubes’.

22 Feb 2023: We are very pleased to see the significant economic and societal impact that our portfolio companies are having. ... Geraldine Rodgers. Geraldine Rodgers, Head of Seed Funds at Cambridge Enterprise, said “We are very pleased to see the significant

23 Feb 2023: patients”. Tags:Image: Test tubes. Stay in touch with the latest updates from Cambridge Enterprise.

22 Feb 2023: The SEIS was announced in the 2012 budget as part of the government’s strategy for stimulating economic growth.

22 Feb 2023: The test will enable patients to seek treatment before complications arise and without the inconvenience, cost and delays associated with current testing methods. ... Kalium Health aims to launch its first test as an approved medical device within four

22 Feb 2023: Consequently, it is often affected by toxic compounds. Demonstrating that a new drug candidate is free from liver toxicity is a key test in the development process, and it is a ... test that most drug candidates fail.

23 Feb 2023: This was the second year for the Enterprise Fund, which was established following the announcement of the SEIS programme in the government’s 2012 budget in order to stimulate economic growth.

22 Feb 2023: The next step is to then test the vaccine in pre-clinical trials—in other words, give the vaccine to mice to check that it is safe to use.

22 Feb 2023: The objective is to build a portfolio of new products to complement and enrich PredictImmune’s prognostic test pipeline in the coming years. ... This will significantly improve clinical outcomes and enhance patient welfare. The team at PredictImmune

23 Feb 2023: genetic test that benefits cancer patients by pinpointing the best drug for treating their tumour; and Inkling, which is developing graphene-enhanced windblade coatings that are resistant to rain erosion, thereby

23 Feb 2023: The company is based upon the research of Professor Chris Abell and Professor Wilhelm Huck (pictured, with Chief Executive Frank Craig), and is developing droplets that serve as ‘miniature test tubes’. ... The X-MAN models, or ‘patients in a test

22 Feb 2023: The UK, EU and Canadian patents expand PredictImmune’s existing patent portfolio and further protect the organisation’s current IP in the development of prognostic tests across a broad range of ... The R&D phase of the test has been completed and the

22 Feb 2023: This was the second year of operation for the Enterprise Fund, which was announced as part of the SEIS programme in the government’s 2012 budget, established to stimulate economic growth.

23 Feb 2023: The SEIS was announced in the 2012 budget as part of the government’s strategy for stimulating economic growth.

22 Feb 2023: Tests with a home assistant platform showed that sentence recognition rate in noisy conditions jumped from 22 percent to 94 percent.

23 Feb 2023: Riverlane is building a simulation engine for microscopic systems to replace expensive laboratory tests with computer simulation.

22 Feb 2023: It does not require installation. The Bolt allows scientists and researchers in drug discovery and plant managers or quality control staff in pharmaceutical manufacturing facilities to perform the necessary tests

23 Feb 2023: of miniaturised tests in tiny picodroplets. ... Among other things, the technology allows tests on individual cells as well as whole “libraries” of cells.

23 Feb 2023: The scale of the potential economic impact of the EU’s proposed restriction can be seen in data submitted by the industry to the ECHA’s stakeholder workshop.

22 Feb 2023: These next-generation iPS cell products will help to improve the efficiency and economics of drug development, and enable the underlying mechanisms of disease to be elucidated in a manner that ... Dr Marcus Yeo, CEO, DefiniGEN, commented: “These

22 Feb 2023: The funds will be used to test the novel p300/CBP inhibitor in late stage, treatment-resistant prostate cancer (up to Phase IIb).

22 Feb 2023: This was the fourth year of operation for the Enterprise Fund, which was announced as part of the SEIS programme in the government’s 2012 budget, established to stimulate economic growth.

22 Feb 2023: valuable proposition for any academic or company that wants to see early stage ground breaking therapeutic technology progress to the clinic for patient benefit and economic return. ... for patient benefit and economic return.”.

22 Feb 2023: This was the fourth year of operation for the Enterprise Fund, which was announced as part of the SEIS programme in the government’s 2012 budget, established to stimulate economic growth.

22 Feb 2023: The objective of the research collaboration with Prof Wade-Martins is to test Mission’s potent and selective USP30 inhibitors in a range of disease models—induced Pluripotent Stem Cells ... There is no objective test, or biomarker, for Parkinson’s

22 Feb 2023: As with IBD, patients with SLE can present with a variable disease course, and it is this variability that makes it an ideal choice for the development of a prognostic test